An interventional study of MagicTouch PTA Sirolimus drug coated balloon and POBA balloon in Peripheral Artery Disease, Atherosclerosis and Arterial Disease of Legs, sponsored by Concept Medical Inc.. Recruiting at 20 sites in 3 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by Concept Medical Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Peripheral Arterial Disease with a site in Taiwan — 8 open to participants now, 8 under way, 3 of them phase 3. Peripheral Arterial Disease · Taiwan.
Among the 26 studies in Peripheral Arterial Disease with a site in Taiwan, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2020, is one of 11 with no phase, and was the 15th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →8 of the 26 studies in Peripheral Arterial Disease with a site in Taiwan are open now. Recruiting first, the newest first:
Shin Kong Wu Ho-Su Memorial Hospital · Sites in Taiwan
Ages 18+
Shin Kong Wu Ho-Su Memorial Hospital · Sites in Taiwan
Ages 18+
Eli Lilly and Company · Sites in Taiwan, United States, Argentina and 15 more countries
Ages 18+
CSL Behring · Sites in Taiwan, United States, Argentina and 32 more countries
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+ · Men only
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 7 · Phase 4 2
First in 2006; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 219 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 212 across the 21 interventional studies, 230 across the 5 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 26 have an industry lead sponsor. The 10 most frequent:
Concept Medical Inc. is the lead sponsor of 9 studies on the registry; 7 are open to participants now.
Concept Medical Inc. has 6 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Peripheral Arterial Disease with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04511247Concept Medical Inc.SirolimUs CoaTed Balloon for The TrEatment of Below The Knee Arterial Disease | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Peripheral Arterial Disease with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of below the knee arterial disease.
The burden of limb loss as a result of peripheral arterial disease (PAD) is high and this problem is set to worsen globally. Treatment of PAD primarily involves revascularisation of the limb. Angioplasty as a first line strategy of revascularization over surgical procedures has been adopted by most vascular centers. Local drug delivery using drug coated balloons (DCB) during angioplasty for PAD can successfully deliver effective local tissue concentrations of anti-proliferative drugs to the lesions in the artery involved in the PAD. This offers the potential for sustained anti-restenotic efficacy.
Randomized trials have shown superiority of Paclitaxel DCBs over just plain-balloon angioplasty for treatment of PAD, and DCB is now considered the standard of care. However, a recent meta-analyses which showed increased mortality at two years in patients treated with paclitaxel DCBs have called into question the safety of paclitaxel based DCBs.
Alternative drugs for DCBs are therefore urgently needed and sirolimus offers an attractive alternative. Compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety. It has a high transfer rate to the vessel wall and has been shown to effectively inhibit neointimal hyperplasia in the porcine coronary model. In the coronary artery interventions, preliminary clinical studies using Sirolimus DCBs have also shown excellent procedural and 6 month patency.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Rutherford class 4 to 6 in the target limb
Intraoperative Inclusion Criteria
Exclusion Criteria:
Known allergy to sirolimus
Intraoperative Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
Device: MagicTouch PTA Sirolimus drug coated balloon
Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
Device: POBA balloon
For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty
Primary patency at 6 months
Primary patency rate at 6 months defined as proportion of subjects with duplex ultrasonography-derived peak systolic velocity ratio of ≤ 2.4 (in absence of target lesion revascularisation)
Time frame: 6 months
Device and procedure related deaths
Proportion of device and procedure related deaths
Time frame: 1,6,12 and 24 Months
All-cause death
Proportion of subjects died by any-cause
Time frame: 1,6,12 and 24 Months
Major target limb amputation
Proportion of subjects with major target limb amputation
Time frame: 6,12 and 24 Months
Target vessel thrombosis
Proportion of subjects with target vessel thrombosis
Time frame: From day 0 to day 14
Proportion of subjects who experienced either death at 6 month or major target limb amputation at 6 month or target vessel thrombosis within 14 days.
Proportion of subjects who experienced either death at 6 month or major target limb amputation at 6 month or target vessel thrombosis within 14 days.
Time frame: Day 0 to day 14, 6 Months
Occurrence of adverse events (AEs), serious AEs and AEs related to device and procedure
Occurrence of adverse events (AEs), serious AEs and AEs related to device and Occurrence of adverse events (AEs), serious AEs and AEs related to device and procedure
Time frame: From Day 0 to 24 Months Follow-up
Procedural Success
Proportion of subjects with procedural success during hospital stay
Time frame: From Day 1 to discharge up to maximum of 30 days
Proportion of subjects who are free from clinically-driven Target Lesion Revascularization (TLR)
Proportion of subjects who are free from clinically-driven TLR
Time frame: 6,12 and 24 Months
Proportion of subjects who are free from clinically-driven Target Vessel Revascularization (TVR)
Proportion of subjects who are free from clinically-driven Target Vessel Revascularization (TVR)
Time frame: 6,12 and 24 Months
Primary patency
Primary patency rate at 12 and 24 months
Time frame: 12 and 24 Months
Restenosis
Proportion of subjects with restenosis
Time frame: 6, 12 and 24 Months
Subjects who are free from MAE
Proportion of subjects who are free from MAE
Time frame: 6 Months
Amputation-free survival
Amputation-free survival
Time frame: 6, 12 and 24 Months
Clinical Success
Proportion of subjects with clinical Success at 6, 12 and 24 months, Clinical success is defined as Improvement in Rutherford classification compared to the pre-procedure Rutherford classification
Time frame: 6, 12 and 24 Months
Device success
Proportion of subjects with device success at day 1
Time frame: Day 1
Technical success
Proportion of subjects with technical success at day 1
Time frame: Day 1
Wound assessment (if any)
Wound assessment (if any)
Time frame: 1, 6, 12, 24 Months
Toe Pressure or ABPI assessment
Toe Pressure or ABPI assessment
Time frame: 6, 12, 24 Months
Health-related quality of life
Mean change from baseline in EuroQol-5Dimensions (EQ-5D) health-related quality of life questionnaire score at 12 and 24 months. The score ranges from 0 to 1, and a higher score means a better outcome
Time frame: 12 and 24 months
Walking impairment
Mean change from baseline in walking impairment questionnaire score at 12 and 24 months. The score ranges from 0% to 100% and a higher score means a better outcome
Time frame: 12 and 24 months
Started Aug 2020 (actual). Primary completion is estimated for Dec 2026, 76 months after the start.
Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 76 months is above that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Concept Medical Inc.